Istituto Europeo Di Oncologia S.r.l.
Verified site
Milan, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effectiveness and safety of a treatment plan for patients with metastatic colorectal cancer, a type of cancer that has spread from the colon or rectum to other parts of the body. The study involves a treatment regimen based on cetuximab, a medication that is a type of antibody designed to target cancer cells. The trial will explore how well this treatment works over three different stages of therapy in patients whose tumors have specific genetic characteristics, known as RAS/BRAF wild type.
Participants in the study will receive a combination of medications, including cetuximab, regorafenib, calcium levofolinate, bevacizumab, irinotecan, fluorouracil sodium, oxaliplatin, and Lonsurf (which contains trifluridine and tipiracil hydrochloride). These medications are administered in various forms, such as tablets or infusions, and work in different ways to help fight cancer. Some of these drugs are chemotherapy agents, which kill cancer cells, while others, like cetuximab and bevacizumab, are antibodies that target specific proteins on cancer cells.
The purpose of the study is to determine how effective this treatment plan is in controlling the cancer and to monitor any side effects that may occur. Participants will be monitored throughout the study to assess their response to the treatment and to ensure their safety. The study will also involve the use of a placebo in some cases to compare the effects of the active medications. The trial aims to provide valuable information on the best ways to treat metastatic colorectal cancer with these medications.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
10 criteria
4 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Milan, Italy
Padua, Italy
Catania, Italy
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Cetuximab is a medication used in this clinical trial. It is a type of therapy known as a monoclonal antibody. Cetuximab works by targeting specific proteins on the surface of cancer cells, which can help slow down or stop the growth of these cells. In this trial, cetuximab is being used to treat patients with a specific type of colorectal cancer that does not have certain genetic mutations, known as RAS/BRAF wild type. The goal is to see how effective and safe cetuximab is when used in combination with other treatments over three different stages of therapy.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.